• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did Rectal Cancer Approval Just Shift AnaptysBio's (ANAB) Investment Narrative?

    Simply Wall St·10/29/2026 21:50:52
    Listen to the news
    • In October 2026, GSK received FDA approval for Jemperli, co-developed with AnaptysBio, as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. The approval was supported by AZUR-1 data and was granted Fast Track, Breakthrough Therapy, Priority Review and a National Priority Voucher.
    • The AZUR-1 trial data suggest Jemperli monotherapy may allow a portion of MSI-H/dMMR rectal cancer patients to avoid surgery and its long term complications. This could reshape how AnaptysBio-linked immunotherapy is used in this niche but clinically significant segment.
    • Attention now turns to what this accelerated Jemperli approval, with its organ sparing potential, could mean for AnaptysBio's broader investment narrative.
    Spot emerging oncology players benefiting from similar treatment shifts by screening for 36 healthcare AI stocks that are aligned with breakthroughs such as AnaptysBio's role in Jemperli.

    What Is AnaptysBio's Investment Narrative?

    To own AnaptysBio, you need to buy into a pretty focused story. This is a royalty driven biotech that depends heavily on its partners actually turning scientific wins into commercial traction. The fresh FDA approval for Jemperli in MSI H/dMMR rectal cancer reinforces that thesis. The drug is GSK’s to commercialize, but the success flows back to AnaptysBio through collaboration economics and royalties, which helped the business become profitable and generate US$352.7m of net income on US$106.1m of revenue.

    In the short term, the thesis leans on execution by partners rather than big internal commercial infrastructure, keeping capital intensity relatively low but putting more weight on deal quality and contract terms. Jemperli’s expanded label adds another potential royalty stream on top of what analysts already model, even though earnings are still forecast to edge down on average over the next three years and interest costs are not yet fully cushioned by recurring profits. Valuation screens flag AnaptysBio as “good value” on P/E and discounted cash flow, which is interesting if you accept that royalty driven earnings with high non cash elements will hold up, but there is a catch...

    There's only one way to know the right time to buy, sell or hold AnaptysBio. Head to Simply Wall St's company report for the latest analysis of AnaptysBio's Fair Value.

    NasdaqGS:ANAB 1-Year Stock Price Chart
    NasdaqGS:ANAB 1-Year Stock Price Chart

    Exploring Other Perspectives

    Fair value estimates for AnaptysBio from the Simply Wall St Community span roughly US$87 to US$168 across three individual views. As a result, you are looking at a wide gap between the lowest and highest conviction. Those opinions were formed before the Jemperli approval news, so treat them as starting points and compare multiple viewpoints before committing capital.

    Explore 2 other AnaptysBio fair value estimates, including one that suggests it could be worth just $87.25!

    Decide For Yourself

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so consider relying on your own judgment.

    Looking For More Investment Ideas Beyond AnaptysBio?

    If the AnaptysBio story has sharpened your interest in targeted healthcare opportunities, it can help to scan a broader field of potential candidates with different risk and income profiles.